Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug’s potential in treating IBD.
Latest Ratings for TEVA
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Barclays | Maintains | Equal-Weight | |
| Jan 2022 | Argus Research | Downgrades | Buy | Hold |
| Oct 2021 | Raymond James | Downgrades | Outperform | Market Perform |
